Light Mode
$0.2220 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.2220, $0.0180 below the day’s high of $0.2400
-0.12 (-34.51%) / 6M
Momentum, market sentiment, and recent alerts
CYDY reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -33.5%.
No alerts for CYDY in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development and potential commercialization of its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its current clinical development activities focus on solid-tumor oncology, including colorectal cancer and metastatic triple-negative breast cancer, and the development of a long-acting version of leronlimab. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.